glutathione s transferase liver isozyme Glutathione-S-Transferases as Potential Targets for Modulation of Nitric Oxide-Mediated Vasodilation Developmental profiles of glutathione S-transferase

Exosomal LncRNA LINC00659 transferred from cancer-associated fibroblasts promotes colorectal cancer cell progression via miR-342-3p/ANXA2 axis

How common is it

Conclusion Glutathione is a real, naturally occurring antioxidant with a meaningful role in cellular health and some promising though still limited evidence for supporting skin radiance

2011 Annual report of the American Association of Poison Control Centers National Poison Data System (NPDS): 29th annual report

Disclosures: Joanne Hsieh: Gordian Biotechnology: Employee, Vinay Kartha: Nothing to Disclose, Hikaru Miyazaki: Nothing to Disclose, Christopher Carrico: Nothing to Disclose, Linda Chio: Gordian Biotechnology: Employee, Gordian Biotechnology: Stock privately held company, Daniel Fuentes: Nothing to Disclose, Dimitry Popov: Nothing to Disclose, Ian Driver: Nothing to Disclose, Chris Towne: Nothing to Disclose, Francisco LePort: Nothing to Disclose, Martin Borch Jensen: Nothing to Disclose 2067 PHARMACOKINETICS, SAFETY AND EFFICACY OF THE NOVEL NON-BILE ACID FXR AGONIST FXR314 IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: RESULTS FROM A PHASE 2 STUDY Eric Lawitz 1 Kathryn Jean Lucas 2 Kris Kowdley 3 Naim Alkhouri 4 Stephen Harrison 5 Fabrice Piu 6 , 1 Texas Liver Institute, 2 Diabetes & Endocrinology Consultants, PC, 3 Liver Institute Northwest, 4 Arizona Liver Health, 5 University of Oxford, 6 Organovo, Inc Background Farnesoid X receptor (FXR) agonism has demonstrated clinical utility for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) but clinical development has been hampered by limited efficacy and adverse events (pruritus, dyslipidemia)